clinical trial · NCT07425522
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)
Genentech, Inc.·phase1·recruiting·n = 93
Diabetic Macular EdemaRO7823653Faricimab
brief summary
The purpose of this study is to evaluate the safety, tolerability, Pharmacodynamics (PD), and Pharmacokinetics (PK) of multiple doses of RO7823653 in participants with DME, administered by intravitreal (IVT) injection as monotherapy and co-administered with faricimab.
started
Apr 21, 2026
primary completion
Nov 17, 2028
completion
Nov 17, 2028
last updated
Apr 23, 2026
official title
A Phase I, Multicenter, Open-Label, Multiple-Ascending Dose Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 Administered by Intravitreal Injection as Monotherapy and in Combination With Faricimab in Patients With Diabetic Macular Edema
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol